Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Meat Science|May 12, 2023
Effects of the use of raw or cooked chickpeas and the sausage cooking time on the quality of a lamb-meat, olive-oil emulsion-type sausageS A Kasaiyan, I Caro, D D Ramos, et al.
Journal of Food Protection|August 9, 2011
Characterization of certain bacterial strains for potential use as starter or probiotic cultures in dairy productsA Monteagudo-Mera, I Caro, L B Rodríguez-Aparicio, et al.
Animal : an International Journal of Animal Bioscience|May 27, 2025
Feeding broccoli and cauliflower to dairy sheep: influence on feed intake, metabolic health status and milk production and compositionA Martín, F J Giráldez, I Mateos, et al.
Dermatology (Basel, Switzerland)|June 5, 2004
T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of actionD Jullien, J C Prinz, R G B Langley, et al.
Cutis|June 1, 1984
Multicenter clinical evaluation of ketoconazole in the treatment of cutaneous fungal infectionsC Brown, I Caro, P Condry, et al.
Food Research International (Ottawa, Ont.)|April 20, 2019
Bootstrap parametric GB2 and bootstrap nonparametric distributions for studying shiga toxin-producing Escherichia coli strains growth rate variabilityE J Quinto, J M Marín, I Caro, et al.
Vaccine|June 25, 2008
Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaquesA Moreno, I Caro-Aguilar, S S Yazdani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1994
Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptorM F Mullarkey, K M Leiferman, M S Peters, et al.
ESMO Open|March 22, 2023
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort studyE Sherman, J L Lee, P R Debruyne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2022
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanomaC Robert, K D Lewis, R Gutzmer, et al.
Pageof 7